Eupraxia Pharmaceuticals Inc T.EPRX

Alternate Symbol(s): T.EPRX.WT | EPRX | T.EPRX.WT.A

Healthcare Biotechnology

Eupraxia Pharmaceuticals Inc. is a Canada-based clinical-stage biotechnology company. The Company is focused on the development of locally delivered, extended-release products. The Company’s lead product candidate, EP-104, is designed to address the significant unmet medical need and market demand for conditions where long-lasting symptom relief is essential to effective treatment. The primary targets for EP-104 have been identified as knee osteoarthritis (OA) and eosinophilic esophagitis (EoE). The product in development for OA is called EP-104IAR and the product in development in EoE is called EP-104GI. DiffuSphere, a proprietary, polymer based micro-sphere technology, is designed to facilitate targeted drug delivery, with extended duration of effect, and offers multiple, highly tunable pharmacokinetic (PK) profiles.

TSX:EPRX - Post by User

Eupraxia Pharmaceuticals Inc

Bullboard Posts

Next >>

Post by kindvalueon Aug 17, 2021 4:15pm

871 Views

Post# 33718451

destruction

EPRX CFO was at Tekmira which held the delivery technology for the RNAi vaccines
Tekmira is now Arbutus
we are talking about the delivery for Moderna and others
the Tekmira team while he was there, decided to massively overpay to get into a hepatitis pre clinical technology and moneitized (sold for near nothing) the majority ownership of the RNAi delivery
actually a good article out on the RNAi technology that was given away
https://www.forbes.com/sites/nathanvardi/2021/08/17/covids-forgotten-hero-the-untold-story-of-the-scientist-whose-breakthrough-made-the-vaccines-possible/?sh=1ea506aa354f

massive destruction of shareholders wealth is on your team

Bullboard Posts

Next >>

Calibre discovers significant gold in Newfoundland